Bone marrow-derived smooth muscle cells (BM-SMCs) have high potential as an autologous cell source of vascular progenitors but normal cell function and turnover frequency may decline with age. In this study we set out to study the effects of organismal ageing on the molecular and functional properties of BM-SMCs.
Introduction
Adult mesenchymal stem cells (MSCs) from bone marrow provide a promising cell source for tissue regeneration. However, stem cell senescence due to donor age or culture conditions appears to limit clinical application of MSCs. 1 Some studies showed that the growth potential of MSCs declines with donor age 2 -4 and this dependence may be species-specific, with human cells displaying lower proliferation potential than mouse cells. 5 In addition to proliferation, the differentiation potential of MSCs was also studied as a function of ageing but the results were variable. Although some studies suggested that osteogenic 3, 6, 7 and chondrogenic 8 differentiation of MSCs decreased with donor age, others reported that the potential of MSCs for osteogenic or adipogenic differentiation 9 as well as tendon regeneration in vivo was independent of ageing. 10 Clearly, more studies are required to understand the effect of organismal ageing on the potential of MSCs for multilineage differentiation and tissue regeneration. Previous studies clearly demonstrated the importance of ageing in the behaviour of cardiovascular cells. 11 In addition to proliferation, donor ageing had a significant effect on mechanical properties of engineered vascular grafts generated from porcine 12 or human smooth muscle cells. 13 Constructs prepared with cells from aged donors showed impaired mechanical strength unless they were modified to express human telomerase reverse transcriptase. 14 -16 These studies clearly demonstrated that a clinically important challenge in vascular tissue engineering is the ability to engineer blood vessels from an easily accessible, autologous source of adult or even elderly donors. Recently, our laboratory showed that bone marrow-derived smooth muscle cells (BM-SMCs) were isolated from neonatal ovine using fluorescence-activated cell sorting (FACS) to sort out BM-MSCs that expressed EGFP under the control of a smooth muscle a-actin (aSMA) promoter. 17, 18 The BM-SMCs exhibited high proliferation potential and expressed vascular smooth muscle cell (V-SMC) markers. 18 Fibrin-based vascular constructs prepared with BM-SMCs displayed receptor-and non-receptor-mediated contractility and could be implanted into the jugular veins of lambs where they remained patent for 5 weeks. BM-SMC-derived tissue-engineered vessel (BM-TEV) exhibited similar structure and collagen deposition to native veins. In contrast to TEV with V-SMCs from ovine umbilical veins, 19 BM-SMCs expressed significantly higher amount of elastin that was deposited in well-organized fibres. Our results suggested that bone marrow-derived progenitor cells can be an autologous source of highly proliferative and functional cells for vascular tissue regeneration.
In this study, we explored the effect of organismal ageing on BM-SMCs and the resulting vascular constructs prepared with these cells. To this end, we employed the aSMA promoter driving EGFP expression to isolate SMCs from BM-MSCs derived from adult or neonatal animals (aBM-SMCs vs. nBM-SMCs). These cells were compared in terms of proliferation potential, clonogenicity, and expression of gene transcripts related to extracellular matrix (ECM) molecules. We also measured the mechanical properties of resulting TEV, i.e. the ability to generate force and respond to vasoactive agonists. Finally, we evaluated the potential of basic fibroblast growth factor (bFGF) to increase proliferation and transforming growth factor-b1 (TGF-b1) to restore contractility of aBM-SMCs vs. nBM-SMCs.
Methods

Isolation of smooth muscle progenitor cells from neonatal and adult ovine bone marrow
Bone marrow samples were aspirated from three neonatal lambs (,3 days old) and three adult sheep (4 -4.5 years old). Isolation of BM-SMCs from BM-MSCs was described previously. 18 Proliferation and clonogenic assays were described before. 17 
Contractility and mechanical properties of tissue equivalents
Cylindrical vascular tissue equivalents containing BM-SMCs in fibrin hydrogels were cultured around a 6.0 mm mandrel of poly(di-methyl siloxane) as described previously. 17 -19 After 2 weeks in culture, the tissue constructs were released from the mandrel and vascular reactivity was measured in an isolated tissue bath. For details, see Supplementary material online.
Quantitative real-time PCR
Total RNA was isolated using the RNeasy kit (Qiagen, Chatsworth, CA, USA) and reverse transcribed using a cDNA synthesis kit (Qiagen) according to the manufacturer's instructions. Quantitative PCR was performed using the iCycler (Bio-Rad Laboratories). The reaction was carried out in a volume of 25 mL containing 1 mL of cDNA, 0.4 mM of each primer (Sigma Genosys, Woodlands, TX, USA), and 12.5 mL of 2Â IQ TM SYBR Green Supermix (Bio-Rad Laboratories). The primer sequences for each gene are shown in Supplementary material online, Table S1 . Each reaction comprised of 40 cycles each with melting at 958C for 10 s, annealing at 558C for 10 s, and extension at 728C for 20 s. The fluorescence intensity was recorded at 728C for 20 s after the extension step of each cycle. The specificity of the PCR products was verified using the melting curve generated by MyiQ software and by electrophoresis on 1% agarose gels. The PCR data analysis was performed as described before. 20 
Statistical analysis
All experiments were conducted with cells from three adult and three neonatal animals in triplicate or quadruplicate (n ¼ 9 -12 per group). Pairwise statistical analysis of the data was performed using a two-tailed Student's t-test using Microsoft Excel software. The data were considered statistically different when P , 0.05.
Results
3.1 nBM-SMCs displayed higher proliferation and clonogenic potential compared with aBM-SMCs BM-SMCs were derived from BM-MSCs by FACS based on expression of EGFP (upper 50% of expressers) under the control of smooth muscle a-actin promoter (P aSMA ) as we described previously. 18 To study the effects of ageing, BM-SMCs were derived from three neonatal (n1, n2, and n3) and three 4-to 4.5-year-old adult lambs (a1, a2, and a3), corresponding to humans between 35 and 40 years old (the lifespan of sheep is about 9 years
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). As shown in Figure 1A , cell morphology and size were significantly different between nBM-SMCs and aBM-SMCs. Neonatal cells were smaller and more elongated, whereas adult cells appeared larger with flat morphology.
To examine the proliferation potential of BM-SMCs, cells from three neonatal and three adult animals were plated in 6-well plates at 1.8 Â 10 4 cells/cm 2 . When confluence was reached (at the indicated times), cells were trypsinized, counted, and replated at the same density. Cell growth was significantly affected by the age of donor animals ( Figure 1B) . Although the population doubling time of nBM-SMCs varied among cells from different animals, all neonatal cells exhibited higher proliferation rate compared with cells from adult donors. Specifically, the average doubling time was 3.67, 3.00, and 2.36 days for n1, n2, and n3, respectively. Cells from one adult donor (a3) exhibited slow proliferation throughout the experiment with an average doubling time of 9.5 days. Cells from the other two adult donors (a1 and a2) divided fast in the beginning of the culture (doubling time: 3.73 and 4.36 days) but their proliferation rate decreased significantly at later passages reaching a doubling time of 13 days or longer. During 10 weeks in culture, neonatal cells were expanded at least a million-fold, whereas adult cells were expanded at most 10 000-fold.
To measure the clonogenic capacity of aBM-SMCs and nBM-SMCs, cells were seeded at clonal density (400 cells in 100 mm dish) and allowed to grow for 10 days. At that time, the cells were fixed and stained with Trypan Blue to visualize and count the number of colonies. Only colonies with diameter .2 mm were counted as those originate from highly proliferative cells, which are more likely to be stem/progenitor cells. As shown in Figure 1C , nBM-SMCs were enriched in highly clonogenic cells compared with aBM-SMCs. Specifically, the fraction of cells that formed .2 mm colonies was 10.3 + 2.5, 6.3 + 1.9, and 19.2 + 5.0% for n1, n2, and n3 vs. 2.8 + 0.7, 2.5 + 1.1, and 3.3 + 0.8% for a1, a2, and a3, respectively. Similar results were found for smaller (2 -3 mm) and larger colonies (3 -4 or .4 mm in diameter) as shown in Figure 1D . In addition, colonies originating from neonatal cells contained smaller cells at a higher density compared with their counterparts from adult cells ( Figure 1E ).
We also examined expression of SMC specific markers in nBM-SMCs and aBM-SMCs (see Supplementary material online, Figure S1 ). Immunostaining showed that both neonatal and adult cells expressed early, intermediate, and late SMC markers such as a-actin, calponin, and myosin heavy chain (MHC).
Higher force generation and vascular contractility by nBM-SMCs compared with aBM-SMCs
Next, we examined the ability of BM-SMCs to generate force by measuring the compaction of three-dimensional (3D) fibrin hydrogels.
To this end, nBM-SMCs or aBM-SMCs were embedded in fibrin gels (10 6 cell/mL) that contained fibrinogen (2.5 mg/mL) and thrombin (2.5 U/mL). One hour after polymerization, gels were released from the plate walls and were allowed to compact the gels over time in the presence of smooth muscle differentiation factors TGF-b1 (2 ng/mL) and ascorbic acid (300 mM). 19, 22, 23 To quantify gel compaction, gels were photographed at the indicated times and their area was measured using Image J software. Although both neonatal and adult cells showed significant contractile properties, the rate of gel compaction was significantly higher for neonatal compared with adult cells (Figure 2A) . Specifically, nBM-SMCs compacted gels to half of their original size within 15 h when compared with 30-50 h for aBM-SMCs. The ultimate extent of gel compaction was also higher in nBM-SMCs containing hydrogels (Figure 2A and B) .
We also evaluated the isometric tension of nBM-SMCs or aBM-SMCs fibrin-based tissue constructs in response to vasoreactive agonists. To this end, we prepared small-diameter cylindrical tissue equivalents by embedding cells in fibrin hydrogels that were allowed to polymerize around 6.5 mm-diameter cylindrical mandrels. After 2 weeks in culture in the presence of TGF-b1 (2 ng/mL) and Ageing of bone marrow-derived smooth muscle cells ascorbic acid (300 mM), cells compacted the gels yielding cylindrical constructs with a wall thickness of 0.49 + 0.06 mm for n1 (n ¼ 8), 0.42 + 0.02 mm for n2 (n ¼ 4), 0.52 + 0.03 mm for n3 (n ¼ 9), 0.54 + 0.05 mm for a1 (n ¼ 7), 0.62 + 0.13 mm for a2 (n ¼ 4), and 0.56 + 0.04 mm for a3 (n ¼ 6). The isometric tension was measured in response to receptor-and non-receptor-mediated agonists and representative plots of force vs. time are shown in Figure 2C . Tissue equivalents based on nBM-SMCs (n1: n ¼ 4, n2: n ¼ 3, and n3: n ¼ 3) exhibited significantly higher isometric tension in response to endothelin-1 (20 nM), U46619 (1 mM), or KCl (118 mM) compared with those prepared with aBM-SMCs (a1: n ¼ 3, a2: n ¼ 3, and a3: n ¼ 3) ( Figure 2D ). These data suggested that donor age may decrease the force-generating ability of BM-SMCs.
Differential SMC-specific marker expression in aBM-SMCs and nBM-SMCs
The higher contractility exhibited by nBM-SMCs prompted us to examine the expression level of several SMC markers including aSMA, calponin, MHC, smoothelin, desmin, and S100A4. To this end, cells were cultured under differentiation conditions [in the presence of TGF-b1 (2 ng/ml) and ascorbic acid (300 mM)] for 5 days and mRNA expression was quantified using qRT-PCR (Figure 3) . The expression level of calponin and MHC varied among cells from different animals. Calponin was significantly higher in two neonatal samples (n1 and n2) but the third one (n3) showed comparable level to adult cells. Similarly, MHC was higher in some (n2) but not all neonatal cells. In contrast, other SMC markers that have been associated with SMC contractile phenotype such as aSMA, 24, 25 smoothelin, 26, 27 and desmin 28 were expressed at 2 + 0.8-fold (n ¼ 6, P ¼ 0.006), 4.3 + 0.09-fold (n ¼ 6, P ¼ 0.004), and 647 + 0.7-fold (n ¼ 9, P ¼ 0.002) higher level in nBM-SMCs compared with aBM-SMCs, respectively (fold increase was based on the average values of all nBM-SMCs or aBM-SMCs).
TEVs from nBM-SMCs exhibited superior mechanical properties
Next, we examined the mechanical properties of vascular constructs prepared from nBM-SMCs or aBM-SMCs. Stress-strain curve showed that elastic modulus of nBM-SMC-based tissue constructs was significantly higher (P , 0.05) than those based on aBM-SMCs ( Figure 4A) . Specifically, the elastic modulus for neonatal constructs was 327.9 + 69.8 kPa (n1, n ¼ 4), 487.8 + 103.1 kPa (n2, n ¼ 4), and 304.6 + 6.9 kPa (n3, n ¼ 3), whereas adult cells yielded tissues with 103.6 + 27. 
Differential gene expression of ECM molecules
Previous studies provided evidence that matrix remodelling and secretion of new ECM by cells affects the mechanical properties of engineered tissue constructs. These studies along with the data presented above prompted us to examine the expression level of several ECM molecules including tropoelastin, collagen type I, and collagen type III using quantitative real-time PCR. V-SMCs from the umbilical veins of neonatal sheep were used as reference. The expression level of collagen I and III varied among cells from different animals. One of the adult cells (a1) showed similar collagen I level as neonatal cells but the others (a2 and a3) exhibited lower expression ( Figure 4C) . Overall, the average expression level of collagen I in nBM-SMCs was significantly higher than that in aBM-SMCs (n ¼ 9, P ¼ 0.009). Collagen type III expression varied between samples and there was no statistically significant difference between neonatal and adult cells ( Figure 4D) . Notably, all three nBM-SMCs expressed tropoelastin transcripts to a much higher level-6-to 100-fold higher-than aBM-SMCs ( Figure 4E ; n ¼ 9, P , 0.000001). Interestingly, aBM-SMCs showed significantly higher tropoelastin and collagen type I levels compared with V-SMCs from neonatal animals, suggesting that BM-derived cells-even when originating from adult animals-express higher levels of these ECM molecules compared with neonatal SMCs from veins.
bFGF enhanced proliferation of aBM-SMCs
As bFGF has been shown to promote proliferation and prevent differentiation of adult and embryonic stem cells, 29 -31 we examined Figure 3 nBM-SMCs expressed higher level of SMC contractility-related genes. Total RNA was isolated from nBM-SMCs or aBM-SMCs cultured to near confluence in the presence of TGF-b1 (2 ng/mL) and ascorbic acid (300 mM) and reverse transcribed to cDNA. Expression of the indicated transcripts was measured by real-time RT -PCR and normalized relative to GAPDH. Each experiment was done with triplicate samples. *P , 0.05.
Ageing of bone marrow-derived smooth muscle cells whether bFGF could also increase the growth rate of the slowly proliferating aBM-SMCs. Addition of 1 ng/mL bFGF increased the number of aBM-SMCs by 1.9-to 2.5-fold, whereas nBM-SMCs increased only by 1.2-to 1.4-fold ( Figure 5A ). The number of both nBM-SMCs and aBM-SMCs displayed the highest increase at 1 ng/mL bFGF and no additional effect was observed up to10 ng/mL. At higher concentration (20 ng/mL), the positive effect of bFGF on aBM-SMCs was less pronounced. Cell morphology also changed dramatically within 24 h of bFGF treatment with both neonatal and adult cells appearing smaller and more elongated ( Figure 5B) . Finally, RT-PCR showed that both aBM-SMCs and nBM-SMCs expressed a similar FGF receptor-1 (FGFR1) level ( Figure 5C ), suggesting that the higher response of aBM-SMCs to bFGF could not be due to higher number of FGFR1 on the surface of these cells.
TGF-b1 enhanced hydrogel compaction by aBM-SMCs
Previous work in our laboratory and others showed that TGF-b1 enhanced V-SMC contractility. 17, 22, 23 Therefore, we examined whether TGF-b1 could improve the force-generating ability of aBM-SMCs. To this end, aBM-SMCs and nBM-SMCs were embedded in fibrin hydrogels that were allowed to compact in the presence or absence of TGF-b1 (2 ng/mL). Fibrinolytic inhibitor 1-aminocaproic acid was added to all samples to eliminate the effects of fibrinolysis on compaction.
In the absence of TGF-b1, nBM-SMCs contracted fibrin hydrogels significantly, reaching 50% of their initial area within 30 -50 h (t 50% ) and 14-20% of the initial area within 96-100 h (final compaction). In contrast, aBM-SMCs showed impaired gel compaction ability, reaching to only 50 -77% of the initial area after 95 -100 h ( Figure 6A) . Addition of TGF-b1 to nBM-SMCs reduced t 50% to 20 -25 h and increased the final extent of compaction to 7-10% of the initial area. Similarly, for aBM-SMCs, TGF-b1 reduced t 50% to 35 -40 h and improved the final extent of compaction to 21-24% of the initial hydrogel area, suggesting that TGF-b1 can restore the force generation deficit of aBM-SMCs to a similar level as that of nBM-SMCs under control conditions (no TGF-b1) ( Figure 6B ).
Discussion
Lack of an easily accessible, autologous cell source is a major barrier for the development of tissue-engineered vascular grafts, especially for elder patients who are most likely to suffer from vascular diseases. Previously, we demonstrated a novel method to isolate pure population of SMCs from BM-MSCs using the aSMA promoter and cell sorting. 18 BM-SMCs showed high proliferation potential and displayed V-SMC-like phenotype and functionality. Moreover, when BM-TEVs were implanted into the jugular veins of lambs, they showed significant matrix remodelling with expression of collagen and elastin that was organized in a fibrillar network similar to native vessels. These results suggested that nBM-SMCs are a promising cell source for development of cell therapeutics and raised the question whether aBM-SMCs would have similar potential. This is an important issue as older patients are more likely to suffer from cardiovascular disease and in need of vascular grafts. To this end, we examined the effects of organismal ageing on BM-SMCs with respect to proliferation potential and vascular function. We found that aBM-SMCs exhibited longer doubling time and limited clonogenic potential compared with nBM-SMCs. Interestingly, bFGF increased proliferation of aBM-SMCs by up to 2.5-fold but had no significant effect on nBM-SMCs, despite a similar level of FGFR1 expression by both cells. This result is in agreement with previous studies showing that bFGF accelerated proliferation and maintained the undifferentiated state of BM stem cells 29, 32, 33 and slow-cycling human multipotent adipose-derived stem (hMADS) cells. 34 In contrast to slow-cycling hMADS cells, which expressed lower amount of bFGF than their fast proliferating counterparts, 34 aBM-SMCs and nBM-SMCs expressed similar levels of bFGF (data not shown) and FGFR1 receptor mRNA, suggesting that other factors may be responsible for the observed difference. Although the mechanism of bFGF's action remains elusive, inhibition of cell cycle arrest factors and downregulation of TGF-b2 35 may account-at least in part-for such effects.
Functional experiments with TEVs prepared from nBM-SMCs or aBM-SMCs revealed differences that depended on donor ageing. Specifically, TEVs from nBM-SMCs exhibited higher hydrogel compaction and vascular contractility compared with aBM-TEVs. These results prompted us to examine whether aBM-SMC function could be further improved by addition of TGF-b1, which was previously shown to promote SMC differentiation of embryonic stem cells, 36, 37 BM-MSCs, 38 -40 bone marrow multipotent stem cells 41 and hair follicle stem cells. 17 TGF-b1 also enhanced the mechanical strength 42 and vascular reactivity of fibrin-based V-TEV. 23 In agreement with these studies, TGF-b1 improved fibrin compaction by aBM-SMCs significantly to the level of nBM-SMCs under control (no TGF-b1) conditions. Collectively, our results suggest that sequential treatment of bFGF in cell culture followed by TGF-b1 during generation of 3D contractile TEV constructs may allow cell expansion and engineering TEVs with enhanced vascular function. The higher contractility of nBM-SMCs correlated with higher expression of SMC markers such as aSMA, smoothelin, and desmin. Expression of aSMA has been correlated with contractility in several studies, 24, 25 whereas smoothelin expression is thought to be an indicator of contractile SMCs. 27 Specifically, smoothelin expression decreased during neointima formation following endothelial injury when SMCs de-differentiated and resumed proliferation. At later times, as proliferation decreased and SMCs re-gained contractility, the level of smoothelin increased again suggesting that smoothelin expression mirrors the state of SMC differentiation. 26 Finally, studies with knockout mice suggested that desmin expression is required for efficient control of vascular contractile and dilatory functions in small resistance arteries. 28, 43 Taken collectively, these results suggest that nBM-SMCs have higher potential to develop a contractile phenotype than aBM-SMCs.
Although the SMC phenotype is still under debate, it is generally accepted that the contractile and proliferative (or synthetic) Ageing of bone marrow-derived smooth muscle cells phenotypes are two ends of a spectrum. 44 SMCs can either proliferate and produce ECM components or develop a contractile phenotype that enables them to respond to mechanical and biochemical stimuli and to control blood pressure and blood flow. Our data showed that nBM-SMCs were not only more proliferative but that they also displayed higher contractility. Although these results may seem to contradict the accepted view of SMC phenotype, it must be noted that SMC contractility was examined after the cells were induced to differentiate in the presence of two soluble factors-TGF-b1 and ascorbic acid-which have been previously shown to promote the contractile SMC phenotype. 17, 22, 23 Culture in a 3D environmentwithin a fibrin scaffold polymerized around a mandrel-might also have contributed to the development of contractile phenotype by constraining hydrogel compaction and inducing cellular alignment in the circumferential direction. 45 Therefore, our experiments suggest the following: (i) under growth-promoting conditions, nBM-SMCs proliferate faster and have higher clonogenic potential, indicating that they are not terminally differentiated SMCs but perhaps SMC-lineage committed progenitors; (ii) under differentiationpromoting conditions, nBM-SMCs exhibited higher SMC differentiation potential than aBM-SMCs, as exemplified by development of superior contractile properties. Our results are in agreement with recent reports demonstrating that ageing decreased not only the proliferation potential but also the myogenic 46 and osteogenic 6,47 differentiation capacity of BM-MSCs. In contrast to MSCs, Zhang et al. 46 reported that ageing did not affect the cardiac regeneration ability of SMCs isolated from the rat aorta. The reason for this result is unclear but the several reports in the literature suggest that the cardiac regeneration potential of injected MSCs is more likely due to indirect effects such as secretion of growth factors that may induce proliferation of resident cardiac cells rather than direct tissue regeneration due to MSC infiltration. 48 Such indirect effects may not be affected by cell ageing.
However, when cells are used to prepare vascular grafts or other engineered tissues, proliferation and development of contractile properties are critical, necessitating development of strategies to restore age-dependent deterioration of cellular function. The differences in mechanical properties and vascular contractility between aBM-SMCs and nBM-SMCs may be at least in part due to differences in matrix remodelling. To examine this possibility, we measured the expression level of ECM proteins such as elastin and collagen type I and III, the main ECM components affecting the mechanical properties of arteries and veins. Interestingly, both aBM-SMCs and nBM-SMCs expressed higher amounts of type I collagen than V-SMCs from neonatal animals. Similar results were observed with type III collagen with the exception of one nBM-SMC sample, which showed similar expression levels as V-SMCs. Notably, nBM-SMCs expressed over 200 times higher level of elastin transcripts compared with V-SMCs. This result supports our previous in vivo experiments, 18 which showed that after implantation into jugular veins of lambs, TEVs from nBM-SMCs synthesized high amounts of elastin that was organized in a fibrillar network very similar to native vessels. In contrast, TEVs from V-SMCs exhibited very little elastin deposition even at 15-week post-implantation. 19 Although inferior to nBM-SMCs, aBM-SMCs expressed significantly higher elastin levels than V-SMCs from neonatal animals, suggesting that BM-SMCs may be a superior cell source for vascular tissue engineering even when they originate from adult donors. We are currently working towards testing this hypothesis in vivo using the ovine animal model that we previously developed in our laboratory. 18, 19 In summary, our study demonstrated that organismal ageing affects the proliferation and clonogenic ability of BM-SMCs as well as the mechanical properties of the resulting fibrin-based vascular constructs. These results correlated with expression of key SMC-specific markers and ECM molecules suggesting a direct relationship between matrix remodelling and vascular function. Interestingly, BM-SMCs from aged animals exhibited higher ECM expression levels compared with V-SMCs from the veins of neonatal animals, suggesting that vascular constructs prepared from these cells may have the potential for implantation and in vivo remodelling. High-throughput genomics and proteomic studies may determine the signalling networks that account for the functional differences between aBM-SMCs and nBM-SMCs and provide potential intervention targets to enhance proliferation and function of vascular cells from adult donors.
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This work was supported by grants from the National Institutes of Health (R01 HL086582) and the John R. Oishei Foundation to S.T.A. Figure 6 TGF-b1 increased fibrin gel contractility in nBM-SMCs and aBM-SMCs. Cells were embedded and polymerized in fibrin and allowed to compact gels in the absence (A) or presence (B) of TGF-b1. At the indicated times, the gels were photographed and their area was measured using Image J software. The ratio of the area of each gel (A) at the indicated time over the initial area (A 0 ) was plotted as a function of time.
